Kinase test may yield big gains for drug-resistant cancers
This shows the experimental strategy for the rational design of kinase inhibitor combination therapies. Expression profiling is used to define what kinases are expressed in cancer cells. Kinase capture using technology developed by the Johnson laboratory is used to measure which of the expressed kinases are activated in cancer cells. The kinome tree on the right shows the comprehensive capture of expressed kinases (yellow dots). Defining which kinases are activated in cancer is then used to design and test combination therapies in preclinical models of triple negative breast cancer. Courtesy of Gary Johnson, Ph.D., University of North Carolina at Chapel Hill
In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases "en masse", enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.
Kinases are proteins expressed in human tissues that play a key role in cell growth, particularly in cancer. Of the 518 known human kinases, about 400 are expressed in cancers, but which ones and how many are actually active in tumors has been difficult to measure. Tremendous efforts have been made to develop kinase inhibitors as cancer treatments, which have resulted in key drugs such as Herceptin, Tykerb, and Gleevec. However, in spite of the effectiveness of this class of cancer drugs, most cancers eventually become resistant. The UNC team has developed a test that can measure both the presence and activity of 60-70 percent of all kinases simultaneously, allowing investigators to see how cancers evade treatment with kinase inhibitors so that they can combine drugs to block resistance.
Gary Johnson, PhD, the project's principal investigator, says, "Single-agent kinase inhibitors are promising in principle, but often fail in practice because the network of tumor kinases learns how to get around the inhibitor, leading to rapid drug resistance. We're very excited about the test our lab has developed because it works very well in a model of breast cancer to predict the success of combination therapies."
Johnson, who is the Kenan Distinguished Professor and chair of the department of pharmacology in the UNC School of Medicine and a member of UNC Lineberger Comprehensive Cancer Center, is working with UNC Breast Center medical director Lisa Carey, MD, UNC Lineberger director Shelley Earp, MD, and surgical oncologist Keith Amos, MD, to perform clinical trials using the technology with the goal of real-time, personalized therapies for breast cancer.
"One of the most frustrating things as an oncologist is when a patient's tumor develops resistance to a treatment," says Carey, who is also a member of UNC Lineberger. "We are excited about the ability to examine tumor samples before, during, and after kinase inhibitor treatment to see how the tumor kinase profile changes, and potentially respond to those changes using different inhibitors."
The team hopes to be able to track and define the kinase 'reprogramming' that takes place in tumors during therapy and to use the new test to identify combinations of drugs that will block the cancer's adaptive behavior that leads to drug resistance. A patent application has been filed for the testing technology.
Provided by
University of North Carolina School of Medicine
-
Combination therapies for drug-resistant cancers
Oct 10, 2011 |
not rated yet |
0
-
Map of substrate-kinase interactions may lead to more effective cancer drugs
Mar 27, 2012 |
not rated yet |
0
-
Research points to new target for stopping colon cancer
Aug 17, 2009 |
not rated yet |
0
-
First-of-its-kind study creates new tool for targeted cancer drug development
Oct 30, 2011 |
not rated yet |
0
-
Two specific agents worse than one in treating endocrine resistant breast cancer cells
Apr 02, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Older prostate cancer patients should think twice before undergoing treatment
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA ...
Cancer
11 hours ago |
not rated yet |
0
|
Two radiotherapy treatments show similar morbidity, cancer control after prostatectomy
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...
Cancer
13 hours ago |
not rated yet |
0
The compound in the Mediterranean diet that makes cancer cells 'mortal'
New research suggests that a compound abundant in the Mediterranean diet takes away cancer cells' "superpower" to escape death. By altering a very specific step in gene regulation, this compound essentially re-educates cancer ...
Cancer
14 hours ago |
4.8 / 5 (12) |
2
|
CT radiation risk less than risk of examination indicator
(HealthDay)—For young adults needing either a chest or abdominopelvic computed tomography (CT), the short-term risk of death from underlying morbidity is greater than the long-term risk of radiation-induced ...
Cancer
15 hours ago |
not rated yet |
0
Team finds mechanism linking key inflammatory marker to cancer
In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
Cancer
20 hours ago |
not rated yet |
0
|
Nobel laureate plays down flu pandemic scaremongering
A Nobel prize-winning scientist Tuesday played down "shock-horror scenarios" that a new virus strain will emerge with the potential to kill millions of people.
No new H7N9 cases in China for a week
No new human cases of the H7N9 virus have been recorded in China for a week, national health authorities said, for the first time since the outbreak began in March.
Genetic predictors of postpartum depression uncovered
Johns Hopkins researchers say they have discovered specific chemical alterations in two genes that, when present during pregnancy, reliably predict whether a woman will develop postpartum depression.
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Child maltreatment increases risk of adult obesity
Children who have suffered maltreatment are 36% more likely to be obese in adulthood compared to non-maltreated children, according to a new study by King's College London. The authors estimate that the prevention or effective ...
Early-life traffic-related air pollution exposure linked to hyperactivity
Early-life exposure to traffic-related air pollution was significantly associated with higher hyperactivity scores at age 7, according to new research from the University of Cincinnati (UC) and Cincinnati Children's Hospital ...